Latest news
25 items- PRSagaliam Acquisition Corp Launches Improved IPF Formula with Vitamin C in Pill and Lozenge Form and Addition of New Slimming NeutraceuticalBAYTOWN, TX / ACCESSWIRE / May 1, 2024 / Sagaliam Acquisition Corp ("SAGA", the "Company") (NASDAQ:SAGA) announced today that Virogentics, Inc., a wholly owned subsidiary of SAGA ("VIRO"), and the Bulgarian product development team, headed by Dr. Lachezar Ivanov and Harry Zhabilov, CSO, have developed a new IPF formula which combines a Vitamin C component with the existing patented compound. This product will be marketed as IPF Immune+ with Vit C. In addition, this new product will be available in both pill and lozenge form providing convenience and a more effective delivery for the users. The team has also begun production of a new slimming formula which will be added to the VIRO nutraceuti
- PRSagaliam Acquisition Corp. Announces Novation Agreement with Enzolytics, Inc.NEW YORK, NY / ACCESSWIRE / April 26, 2024 / Sagaliam Acquisition Corp. ("SAGAU", "SAGA", SAGAR") (the "Company") announced that Sagaliam entered into a Novation Agreement with Enzolytics, Inc. (OTC:ENZC), Biogenysis, Inc. (BGEN), and Virogentics, Inc. (VIRO) (together the "Parties"). Under this restructured agreement SAGA retains 100% ownership of VIRO, ITV-1, the nutraceutical products and license along with VIRO's other assets. This agreement transferred ownership of Biogenysis, Inc. ("BGEN") and it's IP, patents and associated asset being developed back to ENZC in exchange for a reduction of the price from $450,000,000 to $290,000,000 with the dividend of the purchase shares to come dir
- SECSEC Form 25-NSE filed by Sagaliam Acquisition Corp.25-NSE - Sagaliam Acquisition Corp (0001855351) (Subject)
- SECSagaliam Acquisition Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Financial Statements and Exhibits8-K - Sagaliam Acquisition Corp (0001855351) (Filer)
- NEWSSagaliam Acquisition To Delist From Nasdaq On March 6
- PRSAGALIAM ACQUISITION CORP. ANNOUNCES DELISTING OF COMMON SHARES FROM NASDAQNew York, NY, March 07, 2024 (GLOBE NEWSWIRE) -- Sagaliam Acquisition Corp. (NASDAQ: "SAGAU", "SAGA", SAGAR") (the "Company") received a Nasdaq Hearing Withdrawal letter ("Notice") from the Listing Qualifications staff of the Nasdaq Stock Market LLC ("Nasdaq") on March 6, 2024. On May 26, 2023, Staff notified the Company that the market value of its listed securities had been below the minimum $50,000,000 required for continued listing as set forth in Listing Rule 5450(b)(2)(A) for the previous 30 consecutive trading days.1 Therefore, in accordance with Listing Rule 5810(c)(3)(C), the Company was provided 180 calendar days, or until November 22, 2023 to regain compliance with the Rule. O
- SECSEC Form 10-Q filed by Sagaliam Acquisition Corp.10-Q - Sagaliam Acquisition Corp (0001855351) (Filer)
- 13D/GSEC Form SC 13G/A filed by Sagaliam Acquisition Corp. (Amendment)SC 13G/A - Sagaliam Acquisition Corp (0001855351) (Subject)
- 13D/GSEC Form SC 13G filed by Sagaliam Acquisition Corp.SC 13G - Sagaliam Acquisition Corp (0001855351) (Subject)
- SECSEC Form 10-Q filed by Sagaliam Acquisition Corp.10-Q - Sagaliam Acquisition Corp (0001855351) (Filer)
- SECSagaliam Acquisition Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Financial Statements and Exhibits (Amendment)8-K/A - Sagaliam Acquisition Corp (0001855351) (Filer)
- PRSAGALIAM ACQUISITION CORP. ANNOUNCES RECEIPT OF NASDAQ DELISTING LETTER - UPDATEDNew York, NY, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Sagaliam Acquisition Corp. (NASDAQ: "SAGAU", "SAGA", SAGAR") (the "Company") received a delisting notification letter ("Notice") from the Listing Qualifications staff of the Nasdaq Stock Market LLC ("Nasdaq") on December 5, 2023. The Company intends to file an appeal, and take all possible steps to maintain its Nasdaq listing. Following is the core text of the letter received from Nasdaq on December 5, 2023: On May 26, 2023, Staff notified the Company that the market value of its listed securities had been below the minimum $50,000,000 required for continued listing as set forth in Listing Rule 5450(b)(2)(A) for the previous 30 consecutive
- NEWSSagaliam Acquisition Corp. Receives Delisting Notification Letter From Nasdaq
- SECSagaliam Acquisition Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Financial Statements and Exhibits8-K - Sagaliam Acquisition Corp (0001855351) (Filer)
- PRSAGALIAM ACQUISITION CORP. ANNOUNCES RECEIPT OF NASDAQ DELISTING LETTERNew York, NY, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Sagaliam Acquisition Corp. (NASDAQ: "SAGAU", "SAGA", SAGAR") (the "Company") received a delisting notification letter ("Notice") from the Listing Qualifications staff of the Nasdaq Stock Market LLC ("Nasdaq") on December 8, 2023. The Company intends to file an appeal, and take all possible steps to maintain its Nasdaq listing. Following is the core text of the letter received from Nasdaq on December 8, 2023: On May 26, 2023, Staff notified the Company that the market value of its listed securities had been below the minimum $50,000,000 required for continued listing as set forth in Listing Rule 5450(b)(2)(A) for the previous 30 consecutive
- SECSEC Form 10-Q filed by Sagaliam Acquisition Corp.10-Q - Sagaliam Acquisition Corp (0001855351) (Filer)
- SECSagaliam Acquisition Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Sagaliam Acquisition Corp (0001855351) (Filer)
- PRSAGALIAM ACQUISITION CORP. ANNOUNCES A TEMPORARY RESTRAINING ORDER ON ITS EXTENSION PROXY SHAREHOLDER MEETINGNew York, NY, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Sagaliam Acquisition Corp. (NASDAQ: "SAGAU", "SAGA", "SAGAR") ("we", "us", "our", or the "Company") announced today that it received a Temporary Restraining Order on its extension proxy shareholder meeting. On November 20, 2023, the US District Court for the District of Delaware issued a Temporary Restraining Order pursuant to Rule 65(b) of the Federal Rules of Civil Procedure. Sagaliam is restrained and enjoined from convening a shareholders meeting on Nov 21, 2023 or any date thereafter to conduct a shareholder vote on a proposal to extend the Deadline Date, until a preliminary injunction is adjudicated in favor of Sagaliam. A hearing on
- PREnzolytics, Inc. Files Amended December 31, 2022 OTC Report with Audited Financials and Unaudited September 30, 2023 Quarterly DisclosureProvides Updates on SAGA Transaction and on Virogentics, Inc. and Biogenysis, Inc. ProgressALLEN, TX / ACCESSWIRE / November 20, 2023 / Enzolytics, Inc. (OTC:ENZC) (https://enzolytics.com/"https://enzolytics.com/). Enzolytics, Inc. (the "Company") filed an amended December 31, 2022 OTC Annual Report and its delinquent September 30, 2023 OTC quarterly disclosure. The purpose of the amended OTC Annual Report filed today is to include the audited financial statements for December 31, 2022 and 2021. As part of the recently completed sale of the two operating subsidiaries, Virogenetics, Inc. ("VIRO") and Biogenysis, Inc. ("BGEN"), to Sagaliam Acquisition Corp. (NASDAQ:SAGA)("SAGA") post-closing d
- SECSEC Form DEF 14A filed by Sagaliam Acquisition Corp.DEF 14A - Sagaliam Acquisition Corp (0001855351) (Filer)
- SECSEC Form PRE 14A filed by Sagaliam Acquisition Corp.PRE 14A - Sagaliam Acquisition Corp (0001855351) (Filer)
- NEWSEnzolytics Announces The Signing Of The Business Combination Agreement With Sagaliam Acquisition CorpEnzolytics, Inc. (OTC:ENZC) (https://enzolytics.com).Enzolytics, Inc. announces today that it has executed the binding business combination agreement for the sale of Biogenysis, Inc. ("BGEN") and Virogentics Inc. ("VIRO"), the operating subsidiaries of Enzolytics Inc., to Sagaliam Acquisition Corp (NASDAQ:SAGA) in a transaction valued at $450,000,000. The combined company is expected to trade on NASDAQ. The entities have begun the de-SPAC process and are moving on with the closing of this project.Harry Zhabilov, CSO of VIRO, stated, "The SAGA transaction opens numerous opportunities to advance our existing technology, developing new technology and expansion of our growing nutraceutical produ
- PREnzolytics Announces the Signing of the Business Combination Agreement with Sagaliam Acquisition Corp (SAGA)COLLEGE STATION, TX / ACCESSWIRE / September 18, 2023 / Enzolytics, Inc. (OTC:ENZC) (https://enzolytics.com).Enzolytics, Inc. announces today that it has executed the binding business combination agreement for the sale of Biogenysis, Inc. ("BGEN") and Virogentics Inc. ("VIRO"), the operating subsidiaries of Enzolytics Inc., to Sagaliam Acquisition Corp (NASDAQ:SAGA) in a transaction valued at $450,000,000. The combined company is expected to trade on NASDAQ. The entities have begun the de-SPAC process and are moving on with the closing of this project.Harry Zhabilov, CSO of VIRO, stated, "The SAGA transaction opens numerous opportunities to advance our existing technology, developing new tec
- SECSagaliam Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Sagaliam Acquisition Corp (0001855351) (Filer)
- PRSAGALIAM ACQUISITION CORP. ANNOUNCES EXECUTION OF DEFINITIVE BUSINESS COMBINATION AGREEMENT AND RECEIPT OF NASDAQ LISTING DELINQUENCY LETTERNew York, NY, Sept. 15, 2023 (GLOBE NEWSWIRE) -- Sagaliam Acquisition Corp. (NASDAQ: "SAGAU", "SAGA", "SAGAR") ("we", "us", "our", or the "Company") announced today that it received a delinquency notification letter ("Notice") from the Listing Qualifications staff of the Nasdaq Stock Market LLC ("Nasdaq") on July 25, 2023 due to the Company's non-compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the Company's failure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2023 (the "Form 10-K"). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commissi
SAGA FAQ
6 questionsWhat does Sagaliam Acquisition Corp. do?
Sagaliam Acquisition Corp. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses in the telecommunications, media, and technology industries. The company was incorporated in 2021 and is based in Los Angeles, California.Where does SAGA stock trade?
Sagaliam Acquisition Corp. (SAGA) is listed on NASDAQ.What sector and industry is SAGA in?
Sagaliam Acquisition Corp. operates in the Finance sector, Blank Checks industry.When did Sagaliam Acquisition Corp. go public?
Sagaliam Acquisition Corp. (SAGA) completed its IPO in 2022.What companies are similar to SAGA?
Notable peers in the same industry include CVII (Churchill Capital Corp VII), JWSM (Jaws Mustang Acquisition Corp.), HERA (FTAC Hera Acquisition Corp.), CPUH (Compute Health Acquisition Corp.), CONX (CONX Corp.). Compare SAGA side-by-side with any of them on Quantisnow.How can I track SAGA on Quantisnow?
Quantisnow aggregates Sagaliam Acquisition Corp.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SAGA to receive live email and push alerts on every new disclosure.